Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan

Yuichi Tasaka, Akihiro Tanaka, Daiki Yasunaga, Takashige Asakawa, Hiroaki Araki, Mamoru Tanaka, Yuichi Tasaka, Akihiro Tanaka, Daiki Yasunaga, Takashige Asakawa, Hiroaki Araki, Mamoru Tanaka

Abstract

Background: Pharmaceutical intervention enables safe and effective pharmacotherapy by avoiding of adverse drug reactions (ADRs) and efficacy attenuations. Many prescriptions require optimization, and pharmaceutical interventions are inextricably associated with the prevention of potential drug-related problems (DRPs). Although the analysis and understanding of pharmaceutical interventions can lead to improvement in prescription, the analysis of routine pharmaceutical interventions in Japan in insufficient. Thus, we conducted this study to understand potential DRPs by analyzing routine pharmaceutical interventions made by pharmacists in Japan.

Methods: Pharmacists register the details of pharmaceutical interventions (excluding personal patient information) in a web-based database. We classified data of pharmaceutical interventions into 13 DRP types, 43 DRP subtypes, and 10 intervention categories (e.g., avoidance of serious ADRs and renal dosing recommendations). These data were analyzed with a focus on renal dysfunction and polypharmacy.

Results: During the study period, 2376 pharmaceutical interventions were performed. Overall, 68.2% of pharmaceutical interventions were for patients aged over 65 years. The most frequently detected potential DRP was overdosage, followed by omission of prescription, contraindications, and duplication of a drug with similar effect. The main cause of contraindication and overdosage was renal function deterioration, and that of polypharmacy was duplication of a drug with similar effect. Using our original evidence-based approach, we found that 2376 pharmaceutical interventions prevented ADRs for 1678 drugs, with potential cost savings of up to USD 2,657,820.

Conclusions: Our results indicate that the analysis of routine pharmaceutical interventions is beneficial for detecting potential DRPs. Our findings also show that, in an aging society, pharmacists have an important role in providing medication safety, with potential cost savings.

Keywords: Adverse drug reaction; Elderly patients; Pharmaceutical intervention; Polypharmacy; Potential drug-related problem; Renal dysfunction.

Conflict of interest statement

Approval by the Ethical Review Board of Ehime University Hospital was not required because this study did not involve any human or animal subjects.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Causes of avoided contraindications and overdosage. a) overdosage, b) contraindications
Fig. 2
Fig. 2
Main reasons for polypharmacy

References

    1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200.
    1. Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Intern Med. 2011;26:148–153. doi: 10.1007/s11606-010-1518-3.
    1. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:601–608. doi: 10.1592/phco.26.5.601.
    1. Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35:769–781. doi: 10.1007/BF03261973.
    1. PMDA: annual reports. . Accessed 15 Aug 2017.
    1. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001;31:199–205. doi: 10.1046/j.1445-5994.2001.00044.x.
    1. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168:1890–6.
    1. Zed PJ, Abu-Laban RB, Balen RM, Loewen PS, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–1569. doi: 10.1503/cmaj.071594.
    1. Jolivot PA, Pichereau C, Hindlet P, Hejblum G, Bigé N, Maury E, et al. An observational study of adult admissions to a medical ICU due to adverse drug events. Ann Intensive Care. 2016;6:9.
    1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–2012. doi: 10.1056/NEJMsa1103053.
    1. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.
    1. Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.
    1. Tasaka Y, Tanaka A, Ido K, Tanaka M, Araki H. Estimation of the economic impact associated with pharmaceutical interventions. Jpn J Pharm Health Care Sci. 2014;40:208–214. doi: 10.5649/jjphcs.40.208.
    1. Tasaka Y, Yasunaga D, Tanaka M, Tanaka A, Asakawa T, Horio I, et al. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan. Int J Clin Pharm. 2016;38:321–329. doi: 10.1007/s11096-015-0245-6.
    1. Yasunaga D, Tasaka Y, Murakami S, Tanaka A, Tanaka M, Araki H. Economic contributions of pharmaceutical interventions by pharmacists: a retrospective report in Japan. J pharm policy Pract. 2016;10(2) eCollection 2017.
    1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
    1. Adusumilli PK, Adepu R. Drug related problems: an over view of various classification systems. Asian J Pharm Clin Res. 2014;7:7–10.
    1. Hamblin S, Rumbaugh K, Miller R. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach. J Trauma Acute Care Surg. 2012;73:1484–90.
    1. Niwa T. Establishment of antimicrobial stewardship intervention to promote the appropriate use of antimicrobial injection in all inpatients and outcomes evaluation. Jpn J Pharm Health Care Sci. 2013;39:125–33.
    1. Ministry of Health, Labour and Welfare: Outline of patient survey 2014. . Accessed 15 Aug 2017.
    1. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–630. doi: 10.1007/s10157-009-0199-x.
    1. Fujii S, Tanimukai H, Kashiwagi Y. Comparison and analysis of delirium induced by histamine h(2) receptor antagonists and proton pump inhibitors in cancer patients. Case Rep Oncol. 2012;5:409–412. doi: 10.1159/000341873.
    1. Hanlon JT, Landerman LR, Artz MB, Gray SL, Fillenbaum GG, Schmader KE. Histamine2 receptor antagonist use and decline in cognitive function among community dwelling elderly. Pharmacoepidemiol Drug Saf. 2004;13:781–787. doi: 10.1002/pds.952.
    1. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Hernandez AV, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:452–460. doi: 10.1017/ice.2014.88.
    1. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10:e0128004. eCollection 2015.
    1. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.
    1. Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs:analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761–762. doi: 10.1111/j.1447-0594.2012.00868.x.
    1. O’Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P, et al. STOPP & START criteria: A new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1:45–51.
    1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.
    1. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171:1013–1019. doi: 10.1001/archinternmed.2011.215.
    1. Kimura T, Ogura F, Yamamoto K, Uda A, Nishioka T, Kume M, et al. Potentially inappropriate medications in elderly Japanese patients: effects of pharmacists' assessment and intervention based on Screening Tool of Older Persons' Potentially Inappropriate Prescriptions criteria ver.2. J Clin Pharm Ther. 2017;42:209–14.
    1. Verdoorn S, Kwint HF, Faber A, Gussekloo J, Bouvy ML. Majority of drug-related problems identified during medication review are not associated with STOPP/START criteria. Eur J Clin Pharmacol. 2015;71:1255–1262. doi: 10.1007/s00228-015-1908-x.
    1. Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016;81:323–334. doi: 10.1016/j.vascn.2016.04.011.
    1. Kato T, Iwasawa H, Hadame Y, Kato A, Tsukiyama I, Saito H. Economic impact associated with pharmaceutical interventions in cardiovascular disease. Jpn J Pharm Health Care Sci. 2017;43:680–90.
    1. Yano H, Tasaka Y, Yasunaga D, Watanabe S, Ido K, Tanaka M, et al. Survey on the interaction between postoperative oral antibiotics of the clinical path in the ophthalmology ward and medicines brought in by patients, and proposed changes of the oral antibiotics. J Jpn Soc Hosp Pharm. 2014;50:1457–1460.
    1. United Nations: World population prospects 2017. . Accessed 15 Aug 2017.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa